仁和药业：关于控股股东减持股份预披露的公告

Core Points - Renhe Pharmaceutical announced a share reduction plan involving its major shareholder, Renhe (Group) Development Co., Ltd., which currently holds 325,299,386 shares, accounting for 23.2367% of the total shares [2] - The company plans to reduce its holdings by up to 3,000,000 shares, representing a maximum of 0.2143% of the total share capital, within three months starting from 15 trading days after the announcement [2] - Any adjustments to the number of shares to be reduced will be made in the event of corporate actions such as stock dividends, capital increases, or new share issuances, but the percentage of total share capital will remain unchanged [2]